Introduction {#Sec1}
============

Berberine (BBR) is an isoquinoline quaternary alkaloid isolated from *Rhizoma coptidis* (Fig. [1a](#Fig1){ref-type="fig"}), which has been widely used for decades as a nonprescription drug to treat diarrhea in China with good safety \[[@CR1]\]. It has been reported in many studies that BBR possesses diverse bioactivities, including antidiarrheal \[[@CR2]\], antibacterial \[[@CR3], [@CR4]\], anti-inflammatory \[[@CR5]\], antidiabetic \[[@CR6], [@CR7]\] and antihyperlipidemic \[[@CR2], [@CR8]\] effects. Particularly, some recent studies have shown that BBR exhibits inhibitory effects on a variety of tumors, such as lymphoma \[[@CR9]\], breast \[[@CR10]\], colorectal \[[@CR11]\], hepatocellular \[[@CR12]\], lung \[[@CR13]\], esophageal \[[@CR14]\] and pancreatic \[[@CR15]\] cancers. The antitumor activity of BBR has been confirmed by many studies that revealed that BBR could inhibit the growth of cancer cells, induce cell apoptosis and arrest the cell cycle \[[@CR16], [@CR17]\].Fig. 1**Structures of berberine, its derivatives and ETC-1002**.

Some studies have indicated that BBR can inhibit the migration and invasion of tumor cells by affecting the related proteins. For example, the expression of E-cadherin, which is a significant mediator that regulates cell--cell adhesion and is an important molecule for maintaining the morphological and structural integrity of epithelial cells, can be enhanced by BBR in A549 lung cancer cells \[[@CR18]\]. BBR also inhibits the expression of matrix metalloproteinases, an important class of proteins involved in the degradation of the extracellular matrix barrier, as the first step in tumor cell metastasis \[[@CR19], [@CR20]\]. Vascular endothelial growth factor (VEGF) plays a vital role in tumor cell neovascularization. BBR shows an inhibitory effect on VEGF expression in the melanoma cell line B16F-10 \[[@CR21], [@CR22]\]. In colon cancer cells, BBR can significantly inhibit the synthesis of COX-2 and block the activation of the STAT3 signaling pathway induced by COX-2, thereby inhibiting the invasion and metastasis of tumor cells \[[@CR23]\]. Moreover, BBR affects apoptosis-related proteins and pathways, which lead to the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Caspase can be activated by BBR on different tumor cells \[[@CR24]--[@CR26]\]. In addition, BBR inhibits the proliferation of various tumor cells by inducing cell cycle arrest in in vitro cell experiments \[[@CR27]--[@CR29]\].

Mitochondria play a key role in the antitumor effects of BBR. Since most cancer cells have a higher mitochondrial membrane potential (MMP) than nontransformed cells \[[@CR30]\], the positively charged alkaloid can selectively accumulate in mitochondria driven by the negatively charged inner mitochondrial membranes (IMMs). BBR treatment results in decreased MMP, inhibition of respiratory chain complex I, increased mitochondrial permeability transition (MPT), damage to the mitochondrial structure, and decreased mitochondrial oxidative stress and mitochondrial DNA copy number, which together finally causes mitochondrial dysfunction and leads to cell death \[[@CR31]--[@CR33]\].

However, the poor druggability of BBR leads to extremely low plasma exposure and oral bioavailability (\<5%) or acute toxicity after intravenous injection (LD~50~ \< 10 mg/kg), which limits its further development as a potential drug candidate \[[@CR34], [@CR35]\]. To solve these problems, some studies have been carried out that mainly focused on modifications to C-8, C-9, C-10, C-12 and C-13 (Fig. [1b](#Fig1){ref-type="fig"}) \[[@CR36]--[@CR38]\]. Most of these studies focused on lipophilic modifications by introducing long chain alkyl groups. For example, 8-cetylberberine is a long chain alkylate derivative of BBR, which can inhibit the growth of lung cancer in vitro and in vivo \[[@CR39]\]. A palmitate ester at the 9-position of BBR showed enhanced lipid-lowering efficacy \[[@CR40]\]. 13-*N*-Octylberberine derivatives had more effective antimycobacterial activity \[[@CR4]\]. Similarly, the replacement of other nonalkylate moieties also improved BBR activity. Kang et al. synthesized 9-*O*-benzoyl-substituted analogs that exerted triglyceride-lowering effects \[[@CR41]\]. 9-*N*-Substituted BBR derivatives were synthesized and evaluated as a new class of G-quadruplex binding ligands or as cancer immunotherapy agents \[[@CR42]\]. Although the majority of the modifications were centralized at the 9-position, there was a limited report on applying this strategy to improve anticancer activity.

To explore whether the modification of the 9-position could improve the anticancer activity of BBR, we creatively designed and synthesized several compounds by introducing a long alkyl chain branched by hydroxyl group and a methoxycarbonyl group at the 9-position. The substituted group shared a similar structure with the known antihyperlipidemic drug ETC-1002 (Fig. [1c](#Fig1){ref-type="fig"}). We evaluated the effects on proliferation and mitochondrial functions in A549 lung cancer cells. Some compounds exhibited better anticancer effects than BBR. Further, we found that improved cell membrane permeability was crucial in the enhancement of anti-proliferative activity. Therefore, we offer a new approach to develop BBR derivatives as potential anticancer drug candidates.

Materials and methods {#Sec2}
=====================

Synthesis {#Sec3}
---------

The experimental procedures and characterization of all compounds are provided in the Supplementary Information.

Biological assay {#Sec4}
----------------

A549 cells were purchased from the Cell Bank of the Chinese Academy of Sciences (TCHu150, Shanghai, China). The A549 cell lines were maintained in F12K medium (Gibco, CA, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, CA, USA) and cultured at 37 °C in 5% CO~2~.

Cellular proliferation assays (dose-dependent) {#Sec5}
----------------------------------------------

A549 cells were plated into 96-well plates at a density of 3 × 10^4^ cells/mL in triplicate and incubated with escalating concentrations of different compounds for 72 h. CellTiter 96 AQueous One Solution reagent (G5430, Promega) (20 μL) was added per well. The absorbance at 490 nm was measured using a 340PC384 SpectraMAX microplate reader (Molecular Devices). IC~50~ values are reported as the mean of three independent experiments performed in triplicate. The inhibitor concentration range for IC~50~ determinations was 0--200 μM.

Proliferation (time-dependent) {#Sec6}
------------------------------

A549 cells were cultured in 96-well plates at a density of 3 × 10^4^ cells/mL and incubated overnight for adherence before blank treatment or treatment with different compounds. CellTiter 96 AQueous One Solution reagent (G5430, Promega) (20 μL) was added per well. The absorbance at 490 nm was measured using a 340PC384 SpectraMAX microplate reader (Molecular Devices) at 0, 24, 48 and 72 h to determine cell proliferation.

Cell energy metabolic analysis {#Sec7}
------------------------------

A549 cells were cultured in Seahorse XF96 plate at a density of 3 × 10^5^ cells/mL and incubated 24 h for adherence. Then, the medium was replaced by preheated oxygen consumption rate (OCR) assay buffer after the cells were gently rinsed with phosphate-buffered saline (PBS). Each measurement consisted of four injections, and the working compound and final concentration were as follows: injection A, test compounds of various concentrations; injection B, 1 μM oligomycin as an ATP synthase inhibitor; injection C, 0.6 μM FCCP (carbonyl cyanide-*p*-tri-fluoromethoxyphenyl-hydrazone) as a mitochondrial uncoupler; and injection D, 10 μM rotenone and 10 μM antimycin as electron transport chain (ETC) of oxidative phosphorylation inhibitors. After incubation at 37 °C without CO~2~ for \~1 h, the OCR of the cells was measured with a Seahorse XF extracellular flux analyzer.

Compounds cell permeability {#Sec8}
---------------------------

A549 cells at a density of 2.5 × 10^5^ cells/mL were seeded into 12-well plates in triplicate and incubated overnight at 37 °C. After 8 h of exposure to 5 μM different compounds, the medium was removed by aspiration from the wells. Then, the cells were washed three times with ice-cold PBS and lysed on ice for 20 min in 1 mL of lysis buffer (acetonitrile:PBS = 1:2). After sonication, the supernatants were collected and centrifuged for 10 min at 12,000 rpm (4 °C) to remove cell debris. The supernatants were dried in a vacuum, and then 100 μL of acetonitrile was added to the residue. The mixture was vortexed for 3 min, and after centrifugation at 9600 × *g* for 5 min, the supernatant was collected. The concentration of compounds was determined by LC-MS.

Imaging and quantification of TMRE mitochondrial fluorescence staining {#Sec9}
----------------------------------------------------------------------

A549 cells were seeded in 96-well μCLEAR black F-bottom plates at a density of 3 × 10^5^ cells/mL and incubated overnight for adherence. Then, the cells were treated with different concentrations of compounds for 24 h. Next, cells were incubated with 100 nM tetramethylrhodamine ethyl ester perchlorate (TMRE) for 30 min and 1 μg/mL Hoechst 33342 (the final concentration) for the next 10 min in the dark before analysis. Then, the medium was replaced with PBS. Cells were analyzed with an Operetta high content screening system. Images of bright field, TMRE and Hoechst were captured with a 40× microscope, and the fluorescence intensity of TMRE was measured.

Mitochondrial morphological observation by Mito Tracker Green fluorescence staining {#Sec10}
-----------------------------------------------------------------------------------

A549 cells were seeded in 96-well μCLEAR black F-bottom plates at a density of 1.5 × 10^5^ cells/mL and incubated overnight for adherence. Cells were then incubated with different concentrations of compounds for 24 h. Twenty minutes before the end of incubation, a final concentration of 100 nM Mito Tracker Green was added to each well and incubation continued in the dark. After the medium was replaced with PBS, the cells were analyzed with an Opera Phenix high content screening system. Confocal images of Mito Tracker Green were captured under a 63× microscope.

Western blots {#Sec11}
-------------

Proteins of cell lysates or the cytoplasm (without mitochondria) were separated using SDS-PAGE (10%) and transferred to NC membranes. Nonspecific binding was blocked with 5% milk (in TBST) for 1 h, and membranes were probed with antibodies against β-actin (ABGENT, \#AM1021B), cytochrome *c* (11940, Cell Signaling Technologies), Bcl-2 (2764s, Cell Signaling Technologies), cleaved-caspase-3 (9542, Cell Signaling Technologies) and Mcl-1 (5453s, Cell Signaling Technologies). Membranes were incubated with secondary anti IgG-HRP, and chemiluminescence was detected using ECL substrate (GE Healthcare, \#RPN2232) and captured with a ChemiDoc MP imaging system.

Apoptosis analysis by flow cytometry {#Sec12}
------------------------------------

A549 cells (1.5 × 10^5^) were cultured for 24 h in 12-well plates with or without BBR or **B10** (1 μM or 2 μM) treatment. Twenty-four hours after incubation, the cells were harvested, washed with PBS and centrifuged at 400 × *g* for 2 min three times. The cells were resuspended in 100 μL of 1× binding buffer and then incubated with 2 μL of Annexin-V-APC and 2 μL of PI (Meilunbio, MA0220) for 10 min and then diluted with 100 μL of 1× binding buffer. Flow cytometric data were acquired from 1 × 10^4^ cells with a FACS Calibur cytometer (NovoCyte, D2060R), and data were analyzed by Flowjo software.

Statistical analysis {#Sec13}
--------------------

Data were analyzed and are expressed as the mean ± standard error of the mean (S.E.M.). Difference between the two groups were analyzed using Student\'s *t*-tests. The differences among multiple groups were compared by one-way ANOVA. Differences were considered significant when *P* \< 0.05.

Results {#Sec14}
=======

Synthesis {#Sec15}
---------

Eleven new BBR derivatives were designed and synthesized as displayed in Schemes [1](#Sch1){ref-type="fig"}--[5](#Sch5){ref-type="fig"}. As shown in Scheme [1](#Sch1){ref-type="fig"}, taking the commercially available BBR as the starting material, intermediates **1**--**4** were obtained according to a previous report \[[@CR42]\].Scheme 1**a** 195 °C, 30--40 mmHg, 15 min; **b** NaBH~4~, CH~3~OH, 0 °C, 30 min; **c** 2,4-Dimethoxybenzylamine, 120 °C; **d** HCl, CH~3~OH.Scheme 2**a** DMP, DCM, rt, 1 h; **b** (1) oxalyl chloride, dry DCM, DMF, rt, 2 h, (2) **1**, CH~3~CN, reflux, overnight, CH~3~OH; **c** NaBH~4~, CH~3~OH, 0 °C, 1 h; **d** I~2~, KOAc, EtOH, 2 h.Scheme 3**a** Benzyl chloride, K~2~CO~3~, DMF, 50 °C, overnight; **b** (1) oxalyl chloride, dry DCM, DMF, room temperature (rt), 2 h, (2) **2**, Et~3~N, DMAP, dry DCM overnight; **c** NaBH~4~, CH~3~OH, 0 °C, 1 h; **d** Pd/C, H~2~, MeOH, rt, 3 h; **e** I~2~, KOAc, EtOH, 2 h.Scheme 4**a** (1) Oxalyl chloride, dry DCM, DMF, rt, 2 h, (2) **1**, pyridine, CH~3~CN, overnight, reflux; **b** **2**, EDCI, DMAP, dry DCM, rt, overnight; **c** NaBH~4~, CH~3~OH, 0 °C, 1 h; **d** I~2~, KOAc, EtOH, 2 h.Scheme 5**a** (1) Oxalyl chloride, dry DCM, DMF, rt, 2 h, (2) **4**, pyridine, CH~3~CN, overnight, CH~3~OH; **b** NaBH~4~, CH~3~OH, 0 °C, 1 h; **c** I~2~, KOAc, EtOH, 2 h; **d** (1) oxalyl chloride, dry DCM, DMF, rt, 2 h, (2) **4**, pyridine, CH~3~CN, overnight; **e** Pd/C, H~2~, CH~3~OH, rt, 3 h; **f** (1) 1, 7-Dibromoheptane, potassium tert-butoxide, dry DMF, rt, 2 h, (2) HCl (12 N), DCM, 2 h; **g** **1**, CH~3~CN, overnight, reflux; **h** sodium hydroxide, CH~3~OH : H~2~O = 2:1, reflux, overnight.

The synthetic route for compound **B1** is illustrated in Scheme [2](#Sch2){ref-type="fig"}. Starting from the commercially available ETC-1002, intermediate **5** was synthesized using Dess-Martin oxidation (DMP), followed by condensation with intermediate **1**. The reaction was quenched with methanol to give the methyl esterification intermediate **6**. We chose sodium borohydride (NaBH~4~) to achieve the reduction of **6**, followed by oxidation with iodine to afford the final compound **B1**.

Derivative **B2**, with a free carboxyl group, was synthesized as shown in Scheme [3](#Sch3){ref-type="fig"}. Starting from intermediate **5**, one of the carboxyl groups of intermediate **5** was selectively protected with a benzyl group. The resulting intermediate **8** was then condensed with intermediate **2** to give compound **9**. After reduction, deprotection and oxidation reactions, derivative **B2** was obtained.

To further explore the structure activity relationship (SAR), we introduced different side chain substitutions with the same length of 15 carbons and synthesized compounds **B3**--**B7** (Scheme [4](#Sch4){ref-type="fig"}). Different substituted pentadecanoic acids **12**--**15** were reacted with oxalyl chloride and condensed with intermediate **1** to obtain the derivatives **B3**--**B6**. Reagent **16** was condensed with intermediate **2** to give compound **17**. After reduction and oxidation reactions, derivative **B7** was obtained.

To further enrich the diversity of structures, we used similar methods to those used for the synthesis of **B1** and **B2** to synthesize amide derivatives **B8** and **B9** (Scheme [5](#Sch5){ref-type="fig"}). To simplify the synthesis, we removed the two α-methyl groups and obtained ether derivatives **B10** and **B11**. Alkyl bromide **26** was obtained by starting with the reported intermediate **24** according to a previous procedure \[[@CR43]\]. Finally, derivative **B10** was obtained by condensation of intermediate **1** with intermediate **26**. Derivative **B11** was obtained by the heating and hydrolysis of **B10**.

Activities of the BBR derivatives {#Sec16}
---------------------------------

We tested the activity of compound **B1** on the A549 cell line (Table [1](#Tab1){ref-type="table"}), and the results showed a considerable increase in potency (8.6 μM) compared with BBR (54.5 μM). Compound **B1** showed a dramatic increase in cLog *P* (cLog *P* = 3.175) compared with BBR (cLog *P* = −0.771), indicating that **B1** might have better lipophilicity and cell membrane permeability. BBR can inhibit cell proliferation in a dose-dependent manner and achieves complete suppression at the concentration of 60 μM \[[@CR33]\]. To investigate whether **B1** could inhibit cell proliferation as well, A549 cells were incubated in the absence and presence of increasing concentrations of drug (0.5, 1 μM) for 24, 48 and 72 h. BBR and ETC-1002 had no obvious effect on A549 cells (Fig. [2a, b](#Fig2){ref-type="fig"}). However, at the same concentration, **B1** had a dose- and time-dependent effect on cell proliferation (Fig. [2c](#Fig2){ref-type="fig"}). We speculated that one of the reasons might be the improved permeability. To verify our speculation, we conducted a cell membrane permeability experiment in which A549 cells were incubated with BBR and **B1** (5 μM) for 8 h. The results showed that the concentration of intracellular compound **B1** was higher than that of intracellular BBR, which was consistent with the IC~50~ value (Fig. [2e](#Fig2){ref-type="fig"}). Therefore, we found a compound (**B1**) with better permeability and antitumor activity than BBR.Table 1Structures, cLog *P* values^a^ and effects on the survival rate (IC~50~) of A549 cells by **B1**--**B11**.![](41401_2019_346_Tab1_HTML.gif){#d30e1070}^a^cLog *P* means the logarithm of the *n*-octanol/water coefficients by calculationFig. 2Anti-proliferative activities and permeability of compounds B1 and B10 on A549 cells.**a**--**d** Relative optical density (*OD*) value measured at 490 nm on A549 cells after treatment of BBR, ETC-1002, **B1** and **B10** at 0, 24, 48 and 72 h. All data were shown as mean ±  S.E.M of three independent replications. Asterisks indicate *P*-values (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001) of control versus treated groups. **e**, **f** Permeability experiment performed in A549 cells with 5 μM compounds treatment for 8 h to measure intracellular concentration.

Encouraged by the results above, we next introduced different side chain substitutions with the same length of 15 carbons to further investigate the SAR. After deprotecting the methyl group, the acid from compound **B2** completely lost its activity, revealing that the ester moiety was important to maintain the anticancer activity in A549 cells. To simplify the structure, the four α-methyl groups were removed, and compounds **B3**--**B7** were designed and synthesized. Unfortunately, all of them showed dramatic declines in their IC~50~ values toward A549 cells compared with **B1**. Several of the compounds were completely inactive. The above results indicated that the α-methyl groups were beneficial for maintaining the activity. Amide derivatives **B8** and **B9** both displayed weaker activity compared to **B1**, indicating the importance of the oxygen at the 9-position. We then kept the 9-position oxygen to synthesize ester derivatives **B10** and **B11**. To our surprise, compound **B10** exhibited a 60-fold increase in activity compared to BBR (IC~50~ = 0.9 μM). In addition, the acid form compound **B11** had no activity in accordance with the above SAR.

We selected compound **B10** with good potency to test its effects on cell proliferation and cell membrane permeability. As shown in Fig. [2d](#Fig2){ref-type="fig"}, **B10** significantly inhibited cell proliferation in a dose-dependent manner. Moreover, the inhibitory effect of **B10** was stronger than that of **B1**, which matched well with their IC~50~ values in A549 cells. We also evaluated the activity of compounds **B2** and **B11** in the MTS assay (Supplementary Fig. [S1a, b](#MOESM1){ref-type="media"}), and compounds **B2** and **B11** showed no inhibitory effect. There was no doubt that the permeability experiment showed that the concentration of intracellular compound **B10** was higher than that of BBR (Fig. [2f](#Fig2){ref-type="fig"}). The membrane permeabilities of compounds **B2** and **B11** were worse than that of BBR, which demonstrated that the increase in activity was correlated with the increase in permeability (Supplementary Fig. [S1c](#MOESM1){ref-type="media"}).

Due to the positive charge on BBR and its derivatives, they could accumulate into the mitochondria, driven by the strong negative charge on the mitochondrial inner membrane. Moreover, mitochondria play a vital role in the physiological activity of BBR. As a membrane fluorescent potential-dependent mitochondrial indicator dye, TMRE fluorescence would increase with the enlarged MMP difference and vice versa, which could reflect the morphology and membrane potential of the mitochondria. To confirm the effect of the compounds on the mitochondria, we investigated the effects of **B1**, **B10** and BBR on mitochondria via TMRE MMP experiments and fluorescence microscopy experiments.

The results revealed that **B10** dramatically decreased the MMP in a dose-dependent manner, while BBR did not affect the MMP even at the highest concentration (10 μM). **B10** was obviously much stronger than **B1** in the TMRE-based MMP assay, which was consistent with their IC~50~ values (Fig. [3b](#Fig3){ref-type="fig"}). The MMP was almost fully lost after treatment with high concentrations of **B10** (10 μM). In the fluorescence microscopy experiment, the results confirmed that **B10** could lower the MMP in a dose-dependent manner, and the fluorescent signal of TMRE fully disappeared at the 10 μM concentration of **B10**, which was much stronger than that of **B1**. In addition, the fluorescence intensity had no obvious change with BBR treatment, indicating that BBR had no effect on MMP at this concentration (Fig. [3a](#Fig3){ref-type="fig"}). In addition, we noticed that treatment with **B1** and **B10** could lead to changes in mitochondrial morphology. BBR can induce mitochondrial structure collapse and fragmentation at 60 μM in HepG2 cells \[[@CR33]\]. Our results showed that 10 μM **B1** could slightly change the mitochondrial morphology, while 2.5 μM **B10** initiated significant mitochondrial fragmentation. On the other hand, 10 μM BBR treatment had no obvious effects on mitochondrial morphology, as indicated in Fig. [4](#Fig4){ref-type="fig"}. These results revealed that **B1** and **B10** could influence mitochondrial functions and change the normal mitochondrial structure, which could finally lead to the death of cancer cells.Fig. 3B10 reduced mitochondrial membrane potential in A549.TMRE assay in A549 cells following 24 h treatment with BBR, **B1** or **B10**. **a** Representative merged fluorescent images of A549 cells under Operetta 40× objective. Blue: Hoechst for nuclei; orange: TMRE for mitochondria. Images were presented under same parameters. **b** Quantification of TMRE intensity in **a**. All data were shown as mean ±  S.E.M of three independent replications. Asterisks indicate *P*-values (\**P* \< 0.05, \*\**P* \< 0.01) of control versus treated groups.Fig. 4Mitochondrial morphological observation after compounds treatment for 24 h.The fluorescent signal of Mito Tracker Green was observed at the concentrations of 1.25, 2.5, 5.0 and 10 μM **B1**, **B10** and BBR under 63× microscope. Scale bar = 10 μm.

To investigate the effects of the compounds on mitochondrial ETC function, we then investigated the OCR after **B1** and **B10** treatment (Fig. [5](#Fig5){ref-type="fig"}). The results showed that BBR could only slightly inhibit OCR at high concentrations (\>20 μM), while ETC-1002 did not affect the OCR. The OCR dramatically decreased in a dose-dependent manner after treatment with compound **B1**. In summary, the anticancer activity of compound **B1** was better than BBR. Compound **B10** significantly caused a decline in the OCR at the lowest concentration (5 μM) and lead to a sharp and rapid loss of OCR, reaching 30% after 10 min of incubation with high concentration treatment (\>20 μM). In addition, the mitochondrial uncoupler FCCP did not elicit the full percent of oligomycin-blocked ETC respiration, indicating that the ETC respiration capacity of treated A549 cells was suppressed by compound **B10** in a dose-dependent manner. However, compounds **B2** and **B11** had no obvious effect on the OCR (Supplementary Fig. [S1d](#MOESM1){ref-type="media"}, [e](#MOESM1){ref-type="media"}).Fig. 5Inhibition of OCR by BBR (**a**), ETC-1002 (**b**), B1 (**c**) and B10 (**d**) in A549 cells. Mean ±S.E.M.Asterisks indicate *P*-values (\*\**P* \< 0.01, \*\*\**P* \< 0.001) of control versus treated groups.

In addition to proliferation inhibition, we regarded apoptosis promotion as another marker of anticancer efficacy. BBR has been reported to induce apoptosis in SiHa and HeLa cells at doses of 100 μg/mL (297.6 μM) and 250 μg/mL (744.0 μM). In our case, we conducted flow cytometry to evaluate whether **B10** could promote A549 apoptosis with a higher capability than BBR. We chose 1 μM and 2 μM to maintain consistency with the proliferation inhibitory assay, in which 24 h was the intermediate duration of treatment. As shown in Fig. [6a](#Fig6){ref-type="fig"}, the percent of apoptotic cells was significantly increased after **B10** treatment for 24 h in a dose-dependent manner, and **B10** showed increased potency compared to BBR (Fig. [6a](#Fig6){ref-type="fig"}). To further confirm the induced apoptotic mechanism, A549 cells were treated with BBR and **B10** to examine the effect on caspase-3 cleavage by Western blot. As shown in Fig. [6b](#Fig6){ref-type="fig"}, significant caspase-3 cleavage was observed after **B10** treatment, which indicated that **B10** induced A549 cell apoptosis. Mitochondrial membrane depolarization is an early event in apoptosis. Cytosolic cytochrome *c* was necessary for the initiation of the apoptotic program. **B10** treatment induced A549 cell apoptosis, so we next detected the levels of mitochondrial proteins related to apoptosis. After **B10** treatment for 24 h, the expressions of Bcl-2 and MCL-1, the key proteins that prevent apoptosis, were much lower than the levels in the control group as well as the levels in the BBR-treated group (Fig. [6b](#Fig6){ref-type="fig"}). More importantly, the release of cytochrome c from the mitochondria into the cytoplasm was much greater than in the control group after **B10** treatment. These experiments showed that **B10** induces apoptosis in A549 cells and that this induction may be associated with the modulation of mitochondria.Fig. 6B10 induced apoptosis in A549 cells.**a** Flow cytometry plots of Annexin V/PI assay in A549 cells, following 24 h treatment with BBR or **B10**. **b** Immunoblot analysis of A549 cells lysate following 24 h treatment with blank, BBR or **B10** for detection of apoptosis-related proteins. All data were shown as mean ± S.E.M.  of three independent replications. Asterisks indicate *P*-values (  \*\**P* \< 0.01, \*\*\**P* \< 0.001) of control versus treated groups. ^\#\#\#^*P* \< 0.001 of BBR versus the same dose of **B10**.

Discussion {#Sec17}
==========

Although BBR may be used as a lead compound for the prevention of human cancer, the poor druggability of BBR has limited its applications. Inspired by previous studies of BBR derivatives, we introduced long chains at the 9-position to design and synthesize derivatives (**B1**--**B11**) that possessed different substituent groups, such as hydroxyl and methoxycarbonyl. Among these derivatives, compound **B10** showed dramatically increased anti-proliferative activity compared with BBR. Various factors can lead to this phenotype. First, the physical properties and accessibility to cells were considered. We detected the intracellular concentration after treatment for 8 h. **B1** and **B10** both showed significantly higher concentrations compared to BBR due to the introduction of the lipophilic side chains at the 9-position. Thus, higher activities and druggability became possible and were deserving of further research.

Second, the positive charges as another physical property of the compounds were taken into consideration. Positively charged BBR accumulates in the negatively charged inner membrane of the mitochondria. Thus, we assumed that the derivatives could also accumulate in and affect the mitochondria. In addition to the generation of reactive oxygen species, oxidation and reduction of materials and regulation of related signaling, mitochondria, as the energy plant of the whole cell, generates ATP to maintain physiological activities through aerobic respiration. Furthermore, for cancer cells, the specific role varies according to both genetic and environmental factors. Generally, mitochondrial metabolism, bioenergetics, oxidative stress regulation, fission and fusion dynamics, cell death susceptibility, mitochondria biogenesis, turnover, and retrograde signaling can all contribute as mediators of tumorigenesis. The roles of mitochondria differ with different stages of cancer proliferation \[[@CR44]\]. During the initial stages of cancer, genesis can be induced by oxidative stress and signaling pathway alterations in mitochondria. Then, in the growth stage, in addition to the factors mentioned above, mitochondria biogenesis and structural dynamics can be involved. During the survival stage, mitochondria may experience metabolic reprogramming and morphological changes. In the metastasis stage, reprogramming, biogenesis and dynamics are considered to be relative. Recent experimental results indicate that the mitochondrial ultrastructure is involved in the relationship between the bioenergetics and apoptotic (cell life/death decision) roles of mitochondria \[[@CR45]\]. The drop in the MMP and ETC respiration rate is the first stage of the apoptosis process by mediation of cytochrome *c* release. In these processes, the imbalanced distributions of protons and other various ions contribute to the MMP between the two sides of the inner membrane to store energy. Stable MMP is necessary for oxidative phosphorylation and ATP generation. Thus, the MMP assay was regarded as a classical evaluation method for mitochondrial function, in which we chose the potential-related fluorescent dye TMRE to indicate. The intracellular intensity of TMRE is positively correlated to the MMP. Not surprisingly, **B10** represented a significant ability to reduce the MMP compared to BBR and **B1**, indicating more severe mitochondrial dysfunction.

Third, under normal circumstances, mitochondria in the cell are thought to connect with each other dynamically, forming a clear web structure. In the MMP assay, fluorescent images indicated that not only did the MMP decrease, but the structures of some mitochondria were also altered after treatment with **B10**. To further confirm this morphological change with relatively stable intensity, we turned to Mito Tracker Green as an MMP-independent mitochondria labeling tool. In representative images, mitochondria lost their clear and web-like structures in the blank control group, tending to be obscure and dot-like after treatment with **B10**, especially in the relatively high dose groups. Thus, these two aspects---MMP and morphology---reflected the negative effects on mitochondria caused by **B10**, which could lead to obstacles in energy generation, mutual cooperation or dynamic balance among the mitochondria. OCR detection representing respiration capability also consisted of the assumptions mentioned above. On one hand, damages to the energy-generation ability may fail to meet the requirements of cell activities; thus, apoptosis may be induced; on the other hand, the initial anti-proliferative effects observed can also result from enhanced apoptosis. Thus, the apoptosis rate was compared with the control group after treatment with compounds by flow cytometry. The results showed that the rates of apoptosis were significantly improved after treatment with **B10** compared to both the blank control group and BBR group.

Taken together, with the novel modification strategy of introducing a long chain alkyl chain branched by a hydroxyl group and a methoxycarbonyl group at the 9-position, we found one BBR derivative, **B10**, with a higher anti-proliferative effect in A549 cells and had initial trials to investigate the molecular mechanism, in which we thought that the mitochondria and caspase-3-related apoptosis were at least partly involved. Further pharmacological activity evaluations, such as specific targets and druggability, still deserve systematic investigation.
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